A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization
- PMID: 12204526
- DOI: 10.1016/s1535-6108(02)00098-3
A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization
Abstract
Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies.
Comment in
-
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.Cancer Cell. 2002 Aug;2(2):127-37. doi: 10.1016/s1535-6108(02)00097-1. Cancer Cell. 2002. PMID: 12204533
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
